ClinicalTrials.gg
RecruitingNCT05557604STUNNINUpdated Sep 28, 2022

Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer

A Phase 2 interventional study of Decapeptyl in Prostate Cancer, sponsored by Regina Elena Cancer Institute. Recruiting at 3 sites in Italy. Open to male participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-09-28.

Sponsored by Regina Elena Cancer Institute · Phase 2, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 7 months after the study started (first participant enrolled Feb 2021, registered Sep 2022).
  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Planned enrollment
11th of 28
146 · median 120
Started
2021
with 1 other
Phase 2
7 of 28
3 open now
Registered
22nd of 28
by date

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 11th largest by planned enrollment, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 22nd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 90 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, open, randomized phase II trial.

Read the detailed description

Patients will be randomized between SBRT alone (38 Gy in 4 fractions) or SBRT (same schedule) along with short course (6 months) androgen deprivation (STAD). All patients will be treated by intensity modulated radiotherapy. Regarding the combined modality approach, SBRT has to start within 3 months from the first injection of LHRH analogue.

03

Conditions studied

  • Prostate Cancer

Keywords

  • neoplasm, prostate cancer,
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven prostate adenocarcinoma
  • IR or HR in the NCCN definition
  • N0M0 at staging with choline or (preferably) PSMA PET-CT;
  • performance status between 0 and 2;

Exclusion criteria

Exclusion Criteria:

  • Previous local treatment of the prostate with surgery (radical prostatectomy or cryotherapy)
  • Previous radiotherapy to the pelvis
  • Previous chemotherapy for in past 5 years
  • Impossibility to implant fiducials for tracking purposes
  • Impossibility to undergo MRI of the prostate
  • to short term AD
  • Prostate volume >90cc
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
146 participants (estimated)

Study arms

  • No intervention
    arm 1

    SBRT alone 38 GY in 4 fractions

  • Experimental
    arm 2

    SBRT along with short course (6 months) androgen deprivation (STAD)

    Drug: Decapeptyl

Interventions

06

What researchers measure

Primary outcomes

  1. 3-yr bNED survival

    The primary objective of the study is 3-yr bNED survival. If bNED survival is not significantly different between the two experimental arms, the one without AD will be chosen in a future comparison with the standard of care.

    Time frame: 3 years

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Feb 2024, 36 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 36 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2022
First posted
Sep 28, 2022
StartActual
Feb 2, 2021
Primary completionEst.
Feb 2, 2024
CompletionEst.
Feb 2, 2027
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05557604
Lead sponsor
Regina Elena Cancer Institute
Responsible party
Giuseppe Sanguineti (Professore, Regina Elena Cancer Institute) — Principal investigator
First posted
Sep 28, 2022
Start date
Feb 2, 2021
Primary completion
Feb 2, 2024 (estimated)
Completion
Feb 2, 2027 (estimated)
Last update
Sep 28, 2022

Study contacts

Giuseppe Sanguineti, Professor
Contact
giuseppe.sanguineti@ifo.it
0652663015

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion